Altanine Strengthens Scientific Advisory Board with Appointment of Dr. Bruce D. Forrest
Altanine appointed Dr. Bruce D. Forrest, MD, MBA, to its Scientific Advisory Board to support its mission of advancing patient-focused drug-delivery innovation19.
Dr. Forrest brings over three decades of leadership in vaccine, small-molecule, and biopharmaceutical development, previously overseeing pivotal clinical programs at Pfizer and Wyeth that led to regulatory approvals for landmark vaccines like RotaShield®, Prevnar®, and FluMist®1.
His expertise combines clinical insight and global regulatory experience, helping Altanine refine clinical strategy, regulatory pathways, and accelerate the development of its drug-delivery technologies19.
Altanine is expanding its pipeline of advanced drug formulation and delivery technologies aiming to improve the comfort and convenience of everyday medicines, increasing bioavailability and reducing side effects1.
Dr. Forrest expressed enthusiasm about contributing to Altanine’s mission to improve drug delivery and patient outcomes through innovation1.
Company leadership highlighted Dr. Forrest's appointment as a significant step in scaling Altanine’s clinical and regulatory execution19.
Sources:
1. https://www.biospace.com/press-releases/altanine-strengthens-scientific-advisory-board-with-appointment-of-dr-bruce-d-forrest